Free Trial

NOVONIX's (NVX) Sell (E+) Rating Reiterated at Weiss Ratings

NOVONIX logo with Computer and Technology background

Key Points

  • NOVONIX's stock has been given a "sell (e+)" rating by Weiss Ratings, indicating weak performance expectations.
  • In contrast, Wall Street Zen recently upgraded NOVONIX to a "hold" rating, highlighting some mixed analyst opinions on the stock.
  • The company's stock price opened at $1.91, with a fifty-two week range of $0.81 to $3.86, indicating significant volatility in its recent performance.
  • MarketBeat previews top five stocks to own in November.

NOVONIX (NASDAQ:NVX - Get Free Report)'s stock had its "sell (e+)" rating reissued by equities research analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded shares of NOVONIX to a "hold" rating in a research note on Friday, September 26th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Sell".

Read Our Latest Research Report on NOVONIX

NOVONIX Price Performance

NOVONIX stock opened at $1.91 on Friday. NOVONIX has a fifty-two week low of $0.81 and a fifty-two week high of $3.86. The firm's 50-day simple moving average is $1.58 and its 200 day simple moving average is $1.34. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 0.93.

NOVONIX Company Profile

(Get Free Report)

NOVONIX Limited provides battery materials and development technology for battery manufacturers, materials companies, automotive original equipment manufacturers (OEMs), and consumer electronics manufacturers in North America, Asia, Australia, and Europe. It operates through Battery Materials and Battery Technology segments.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in NOVONIX Right Now?

Before you consider NOVONIX, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NOVONIX wasn't on the list.

While NOVONIX currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.